What do you think are the major barriers or causes which stop nano particles from entering into mainstream treatment of lethal diseases in spite of success at lab scale?
@ Seema, I think it is mainly the ethical issues. The toxicity for a longer term is not systematically studied so far . The doses also not properly fixed. I hope, in near future all hardels are removed only we have to strengthen the research part.
@ Seema, I think it is mainly the ethical issues. The toxicity for a longer term is not systematically studied so far . The doses also not properly fixed. I hope, in near future all hardels are removed only we have to strengthen the research part.
Apart from long term studies dealing with toxicity and fate of the nanostuff, one major concern has to do with long term shelf stability. Drying can significantly alter the nanoentities making them microentities.
Dear Saroj,
There are some of the barriers in commercialisation of nanoformulations including: 1. Toxicity of nanoparticles for the long period of time that make them as dangerous particles. 2. Bio-distribution (pharmacokinetic and pharmacodynamic) issue of nanoparticles that is very matter for the clearance of them. 3. Bio-compatibility and bio-availability of nanoparticles are also most important, because we need to find nanoparticles which are affordable for body and accessible for the costumers.
It is so challenging to get stable nanoparticles with high drug loading. Moreover, active targeting has many limitations that impede its applicability.
- Badges
- Science topic
- Similar topics
- Chemistry
- Nanotechnology
- Nano